Expert discussion on the evolving role of immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) from symposium sessions at the virtual 2020 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer are reviewed in this article. Masahiro Tsuboi, National Cancer Centre Hospital East, Tokyo, Japan, chaired and opened the session by exploring the role of immuno-oncology in the management of unresectable Stage III non-small cell lung cancer (NSCLC).
Latest articles
All articles
15 Mins
31st
March
Endometrial Cancer Research in 2024
Endometrial cancer is one of the most common gynaecological cancers in high-income countries and, for many years, has been associated…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.

5 Mins
29th
October
From Podium into Practice: Working Together to Revolutionise Cancer Care in the Real World
Cancer is on course to be the leading cause of death in the EU by 2035. Europe’s population is ageing rapidly, and obesity rates continue…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.

8 Mins
29th
October
Novel Approaches to Treat Glioblastoma Multiforme
Glioblastoma multiforme (GBM), central nervous system (CNS) WHO Grade 4 astrocytoma, is an almost uniformly lethal disease…
Rate this content's potential impact on patient outcomes Submit Rating Average rating / 5. Vote count: No votes so far! Be the first to rate this content.